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Hydrogen sulfide (H2S) is the last gaseous transmitter identified in mammals, and
previous studies have reported disparate conclusions regarding the implication
of H2S in cancer progression. In the present study, we hypothesized that
sodium hydrosulfide (NaHS), a fast H2S-releasing donor, might interfere with
the mitochondrial respiratory chain of tumor cells, increase tumor oxygenation,
and potentiate the response to irradiation. Using electron paramagnetic
resonance (EPR) oximetry, we found a rapid increase in tumor pO2 after
NaHS administration (0.1 mmol/kg) in two human tumor models (breast MDA-
MB-231 and cervix SiHa), an effect that was due to a decreased oxygen
consumption and an increased tumor perfusion. Tumors irradiated 15 minutes
after a single NaHS administration were more sensitive to irradiation compared
with those that received irradiation alone (increase in growth delay by 50%). This
radiosensitization was due to the oxygen effect, as the increased growth delay
was ab...
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Abstract
Hydrogen sulﬁde (H2S) is the last gaseous transmitter iden-
tiﬁed in mammals, and previous studies have reported disparate
conclusions regarding the implication of H2S in cancer progres-
sion. In the present study, we hypothesized that sodium hydro-
sulﬁde (NaHS), a fast H2S-releasing donor, might interfere with
the mitochondrial respiratory chain of tumor cells, increase
tumor oxygenation, and potentiate the response to irradiation.
Using electron paramagnetic resonance (EPR) oximetry, we
found a rapid increase in tumor pO2 after NaHS administration
(0.1 mmol/kg) in two human tumor models (breast MDA-MB-
231 and cervix SiHa), an effect that was due to a decreased
oxygen consumption and an increased tumor perfusion. Tumors
irradiated 15 minutes after a single NaHS administration were
more sensitive to irradiation compared with those that received
irradiation alone (increase in growth delay by 50%). This radio-
sensitization was due to the oxygen effect, as the increased
growth delay was abolished when temporarily clamped tumors
were irradiated. In contrast, daily NaHS injection (0.1 mmol/kg/
day for 14days)didnotprovide any effect on tumor growth in vivo.
To understand these paradoxical data, we analyzed the impact of
external factors on the cellular response to NaHS. We found that
extracellular pH had a dramatic effect on the cell response to
NaHS, as the proliferation rate (measured in vitro by BrdU incor-
poration) was increased at pH ¼ 7.4, but decreased at pH ¼ 6.5.
Overall, our study highlights the complex role of environmental
components in the response of cancer cells to H2S and suggests a
new approach for the use of H2S donors in combination with
radiotherapy. Mol Cancer Ther; 15(1); 154–61. 2015 AACR.
Introduction
Hydrogen sulﬁde (H2S) has emerged as an important endog-
enous modulator and is now considered the third member of
the gasotransmitter family, along with nitric oxide (NO) and
carbon monoxide (CO; ref. 1). H2S is an enzymatically pro-
duced small molecule that can freely cross biologic membranes
and exert a wide range of actions. H2S most known effect is the
reversible inhibition of the last mitochondrial electron accep-
tor, cytochrome C oxidase (2). Other H2S targets have been
reported so that H2S appears also implicated in the cardiovas-
cular system. H2S dilates rat and human blood vessels by
opening smooth muscle cells Katp channels (3). Other cardio-
vascular effects of H2S, such as protection against ischemia/
reperfusion injury, have been described (4). Moreover, H2S
effects are also found in the nervous and endocrine systems, as
well as in inﬂammation (5). Since the discovery that H2S is
important for physiologic and pathologic processes, develop-
ment and clinical applications of injectable donors allowing
controlled and safe administration of the molecule have
attracted growing interest (6). Because of their commercial
availability, preclinical and clinical studies have been con-
ducted using fast H2S-releasing inorganic salts, such as sodium
hydrosulﬁde (NaHS) and sodium sulﬁde (Na2S; ref. 7).
Until now, investigations in cancer research have mainly
focused on the effects of H2S on proliferation and survival of
cancer cells (8–11). However, controversial results exist, as
evidenced by the reported increased (8) or decreased (9)
proliferation of colon cancer cells following NaHS treatment.
A study showed that H2S derived from NaHS may confer
intrinsic radioresistant properties to cancer cells (12). However,
the beneﬁcial effects of H2S as cotreatment to radiotherapy
have never been studied in vivo. We paid attention to this latter
aspect because it was previously shown that NO, another
gaseous mediator, radiosensitizes tumors in mice (13–15). It
was shown that NO acts as an intrinsic radiosensitizer but also
acts through an "oxygen enhancement" effect, alleviating tumor
hypoxia, which is a major cause of resistance to radiotherapy
(16, 17). pO2 values of 2.5 mmHg or less are characteristic of
advanced solid tumors in a wide range of human cancers (18),
and oxygen tensions below 10 mmHg are estimated to signif-
icantly reduce radiosensitivity (19). It is related to the fact that
oxygen enhances water radiolysis and ﬁxes DNA damage fol-
lowing radiation treatment.
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In the present study, we considered the potential effect of
NaHS administration on tumor hypoxia and response to irra-
diation. Considering the origins of tumor hypoxia (18), the
effects of NaHS treatment on the delivery of oxygen from the
blood and on oxygen consumption by cancer cells were exam-
ined. We also investigated in vitro and in vivo impact of NaHS
on cancer cell growth when used as a single therapeutic
compound.
Materials and Methods
Cell culture and reagents
Thehuman cervix carcinoma SiHa and thehumanbreast cancer
MDA-MB-231 cell lines were from the American Type Culture
Collection (ATCC). SiHa cancer cells were obtained in 2012, and
MDA-MB-231 cancer cells were obtained in 2011. Cell lines were
authenticated by the provider and were frozen in liquid nitrogen
soon after arrival. In this study, aliquots were thawed and early
passage (<20 passages) cells were used. Cells were grown in
DMEM þ Glutamax (Life Technologies) containing 4.5 g/L glu-
cose supplemented with 10% heat inactivated FBS and 1%
penicillin–streptomycin. For the experiments, culture medium
containing no glutamine was used. pH was buffered with 10
mmol/L PIPES or 3.7 g/L sodium bicarbonate. For the oxygen
consumptionmeasurements, where no incubation timewas used,
pHwas adjusted to 6.5, 7.0, or 7.5 withHCl 0.1mol/L andNaOH
0.1 mol/L solutions. All cultures were kept at 37C in 5% CO2
atmosphere. NaHS (Sigma) crystals were dissolved in physiologic
saline (NaCl 0.9%). Rotenone (Sigma), amitochondrial complex
I inhibitor, was diluted inDMSO. Solutions were freshly prepared
before all experiments.
Oxygen consumption rate
The oxygen consumption rate (OCR) of intact whole cells
was measured using a Bruker EMX EPR spectrometer operating
at 9.5 GHz as previously described (20). Adherent cells were
trypsinized and resuspended in fresh medium (107 cells/mL).
Hundred mL of the cell suspension was mixed with 100 mL of
20% dextran to avoid agglomeration and was sealed in a glass
capillary tube in the presence of 0.2 mmol/L of a nitroxide
probe acting as an oxygen sensor (15N 4-oxo-2,2,6,6-tetra-
methylpiperidine-d16-
15N-1-oxyl, CDN isotopes). Cells were
maintained in 37C during the acquisition of the spectra. EPR
linewidth was measured every minute and reported on a
calibration curve to obtain the oxygen concentration (13).
OCR was determined by the absolute value of the slope of the
decrease in oxygen concentration in the closed capillary tube.
Cell proliferation
Cell proliferation was assayed with a 5-bromo-20-deoxyur-
idine (BrdU)–ELISA-based method (Roche) following the pro-
vider's instructions. Cells were incubated in the presence of
BrdU (a nucleotide analogue) during 4 hours, and the amount
of BrdU incorporated in the cells was assessed by colorimetric
measurements using a plate reader (SpectraMax M2e; Molecu-
lar Devices).
Glucose consumption
Extracellular glucose consumption was measured from super-
natant of cultured cells. Metabolite concentration was enzymat-
ically quantiﬁed on deproteinized samples with a CMA600 ana-
lyzer (CMA Microdialysis AB). Glucose consumption was nor-
malized to protein content using the Pierce BCA Protein assay
(Thermo Scientiﬁc).
Intracellular ATP quantiﬁcation
Total intracellular ATP was measured by the ATP Determi-
nation Kit (Life Technologies) according to the manufacturer's
protocol. Cells were washed twice with PBS and lysed in the
buffer recommended by the manufacturer (10 mmol/L Tris, 1
mmol/L EDTA, 100 mmol/L NaCl, 0.01% Triton X-100). Cell
lysates were added to a reaction mixture containing luciferase
and luciferine for bioluminescence measurements using a plate
reader (SpectraMax M2e; Molecular Devices). A standard curve
was generated with known ATP concentrations in the same
conditions. Intracellular ATP concentration was normalized to
protein content using the Pierce BCA Protein assay (Thermo
Scientiﬁc).
pHi measurements
Cells were incubated for 30 minutes at 37C in Hank's
medium (Sigma) containing 7 mmol/L 5-(and-6)-Carboxy
SNARF-1, Acetoxymethyl Ester, a ﬂuorescent pH indicator (Life
Technologies). Cells were washed with Hank's medium, and
ﬂuorescence (excitation 485 nm; emission 580 and 642 nm)
was detected using a plate reader (SpectraMax i3; Molecular
Devices). Fluorescent values were converted into pH values
using the nigericin/high Kþ solution calibration technique
according to the manufacturer.
Mouse models and in vivo experiments
Five-week-old female NMRI nude mice (Janvier Labs) were
intramuscularly injected with 107 SiHa or MDA-MB-231
human cancer cells in the rear leg. Tumor xenografts were
allowed to grow up to 8 mm before experimentation. For the
treated groups, NaHS was dissolved in physiologic saline (NaCl
0.9%) and given by intraperitoneal injection (100 mmol/kg
body weight). Control animals were treated with physiologic
saline only. Animals were anesthetized by inhalation of iso-
ﬂurane mixed with air (3% induction, 1.8% maintain for a
minimum of 15 minutes before any measurement). All animal
experiments were conducted in accordance with national ani-
mal care regulations.
Tumor oxygenation
EPR oximetry using charcoal (CX 0670-1; EM Sciences) as
oxygen sensorwas used to dynamically evaluate changes in tumor
oxygenation after treatment with NaHS, using a protocol
described previously (21). EPR spectra were recorded using an
EPR spectrometer (Magnettech), with a low-frequencymicrowave
bridge operating at 1.2 GHz and an extended loop resonator. A
suspension of charcoal was injected into the center of the tumor
1 day before measurement (100 mg/mL; 50 mL injected, particle
size of 1–25 mm). The localized EPR measurements correspond
to an average of the pO2 values in a volume of approximately
10 mm3 (22). For the experiments, baseline values were per-
formed after mice were anesthetized to determine the oxygen
status of tumors before injection of the treatment. Then, the effect
of NaHS was measured by following tumor pO2 for 1 hour after
the single injection. Body temperature of the mice was kept at
37C throughout the experiment.
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Tumor perfusion
The Patent blue staining method was used to obtain an
estimation of the tumor perfusion fraction using a protocol
described previously (23). Fifteen minutes after NaHS or phys-
iologic saline treatment, 100 mL of Patent blue (Sigma) solution
(1.25%) was injected in the tail vein of the mice. After 1 minute,
mice were sacriﬁced and tumors were excised. To evaluate the
tumor perfusion fraction, each tumor was cut into two size-
matched halves, and the percentage of stained area of the
whole cross-section was determined using an in-house program
running on MatLab.
Tumor radioresponse
The tumor was locally irradiated (137Cs g-irradiator) with a
single dose of 16 Gy. Mice were anesthetized, and the tumor was
centered in a 3-cm diameter circular irradiation ﬁeld. Irradiation
was given 15 minutes after injection of NaHS or physiologic
saline. After radiotherapy, tumor growth was determined using
a caliper until the diameter reached 14 mm, time at which the
mice were sacriﬁced.
Statistical analysis
All results are expressed as mean  SEM. Differences between
groups were analyzed using the unpaired Student t test or ANOVA
whenmore than two groupswere compared. The value of P < 0.05
was considered statistically signiﬁcant.
Results
NaHS injection increases oxygenation of hypoxic tumors in
mice
Hypoxia is a major cause of resistance to radiotherapy in solid
tumors. Therefore, we analyzed the capability of the fast H2S-
releasing donor NaHS to increase tumor oxygenation in two
human tumor models. As H2S is rapidly oxidized in biologic
samples, local tumor oxygenation was monitored before (base-
line) and during 1 hour after intraperitoneal injection of NaHS
(100 mmol/kg) or vehicle [physiologic saline (NaCl 0.9%)].
Oxygen levels were quantiﬁed using EPR oximetry, a sensitive
method allowing continuousmeasurement of pO2 from the same
site over time (21). Our results showed that, as compared with
control groups, NaHS injection rapidly increased tumor pO2 in
human breast MDA-MB-231 (Fig. 1A) and human cervix SiHa
(Fig. 1B) xenografts, where signiﬁcant increased oxygenation was
observed 15 minutes after NaHS injection. Note the different
scales used in Fig. 1A and Fig. 1B. Interestingly, the signiﬁcant
effect on tumor pO2 correlated with the time to reach maximum
plasmatic H2S concentration following an intraperitoneal injec-
tion of NaHS (24).
NaHS inhibits cellular oxygen consumption and enhances
tumor perfusion
To understand the signiﬁcant increase in pO2 induced by
NaHS in hypoxic tumors, oxygen consumption of cancer cells
was ﬁrst studied. We intended to determine in vitro how NaHS
inﬂuences the OCR of MDA-MB-231 and SiHa cancer cells. In
aqueous solution, H2S derived from dissolved NaHS is in
equilibrium with the poorly membrane permeant HS þ Hþ
with a pKa of 6.9 (25). We therefore analyzed the inﬂuence of
different extracellular pH (pHe) on OCR inhibition by NaHS.
As shown in Fig. 2A and B, exposure to 50 mmol/L NaHS
instantaneously inhibited OCR in MDA-MB-231 and SiHa
tumor cell lines, and the response was dependent on pHe. We
observed that OCR inhibition was more effective when pHe
decreased. After that to examine the concentration response to
NaHS, MDA-MB-231 and SiHa cells were treated with 0, 1.5,
25, 50, and 100 mmol/L NaHS in the presence of acidic pHe
(Fig. 2C and D). We observed a signiﬁcantly reduced OCR at 50
mmol/L NaHS in both cancer cell lines. At lower sulﬁde con-
centration, the afﬁnity of H2S for the heme center of cyto-
chrome C oxidase is too low to produce detectable inhibition of
the enzyme (2), justifying the absence of OCR inhibition at
lower NaHS concentrations. Hence, the trend toward an
increased OCR in cells exposed to 1.5 mmol/L NaHS corrobo-
rates that H2S may also act as a mitochondrial electron donor
when present in low concentration (26). At 100 mmol/L NaHS,
the same OCR inhibition as with rotenone, an inhibitor of
mitochondrial respiration, was observed. To ensure that OCR
inhibition was not due to cell mortality caused by the exper-
imental conditions, viability assays were also performed. As
shown in Supplementary Fig. S1A–S1D, no cell death was
found.
Figure 1.
NaHS injection increases tumor pO2. Tumor pO2 was monitored in
MDA-MB-231 (A) and SiHa (B) tumors by EPR (L-band) oximetry before
(baseline) and after NaHS (100 mmol/kg, *) or vehicle (NaCl 0.9%, *)
i.p. injection (60 minutes). Each point represents mean pO2  SEM.
 , P < 0.05;  , P < 0.01;  , P < 0.001. ANOVA and Bonferroni post-test
(n ¼ 5–7/group).
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Blood perfusion was also investigated. Measurements were
performed 15 minutes after NaHS injection using the Patent
blue staining assay. This method, involving the injection of a
dye in the systemic circulation of the mice, has previously been
validated and compared with DCE-MRI (23). We observed
that, as compared with vehicle-treated mice, the perfused area
was increased in MDA-MB-231 (Fig. 3A) and SiHa (Fig. 3B)
xenografts of NaHS-treated (100 mmol/kg) mice, indicating that
increased perfusion also accounts for the improved tumor O2
level following NaHS treatment.
NaHS radiosensitizes tumors by an "oxygen enhancement"
effect
To investigate the therapeutic relevance of NaHS as a potential
radiosensitizer, regrowth delay assays were performed in MDA-
MB-231 tumors. Tumor growth curves are presented in Fig. 4A.
Without irradiation, no difference in tumor growth was observed
after a single i.p. administration of NaHS or vehicle. In irradiated
groups, the regrowth delay to reach a 12-mm tumor diameter
was 13.6  2 days for irradiation þ vehicle and 20.5  3.5
for irradiation þ NaHS, suggesting that NaHS administration
15minutes before irradiation increased sensitivity of tumors by a
factor of 1.5 (Fig. 4B). To highlight that NaHS radiosensitizes
tumor through an oxygen effect, we also used a group of mice
receiving irradiationþNaHSwhose legs were temporarily ligated
to induce complete hypoxia at the time of irradiation. As the
regrowth delay was similar to the irradiation þ vehicle group
Figure 2.
NaHS treatment decreases cancer cells OCR. OCR of viable MDA-MB-231 and SiHa cancer cells was measured in vitro using EPR (X-band) oximetry. A
and B, cancer cells treated with 50 mmol/L NaHS or vehicle (NaCl 0.9%) in the presence of different pHe values. C and D, cancer cells treated with
increasing NaHS concentration or vehicle in the presence of pHe ¼ 6.5. Each bar represents mean OCR  SEM.  , P < 0.05;  , P < 0.01;  , P < 0.001; ns, not
signiﬁcant. Two-sided t test (A and B; n ¼ 3) or ANOVA and Dunnett post-test (C and D; n ¼ 3).
Figure 3.
NaHS injection increases blood perfusion. Perfusion of MDA-MB-231 (A)
and SiHa (B) tumors was measured by Patent blue staining 15 minutes
after NaHS (100 mmol/kg) or vehicle (NaCl 0.9%) i.p. injection. Each
bar represents mean colored area  SEM.  , P < 0.05;  , P < 0.01.
Two-sided t test (n ¼ 4–5/group).
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(Fig. 4B), this experiment showed that oxygen was necessary for
NaHS to increase radioresponse.
Chronic NaHS injection alone is inactive to control tumor
growth in mice
The potential inhibitory or stimulatory effect of the H2S
donor on tumor growth was also evaluated in vivo. Nude mice
bearing MDA-MB-231 xenografts were daily i.p. injected with
NaHS (100 mmol/kg/day) or vehicle (physiologic saline), and
tumor diameter was measured until tumors reached 14 mm in
diameter. Results showed that daily NaHS injection was inac-
tive to control tumor growth, as no difference between NaHS-
treated and vehicle-treated MDA-MB-231 tumor-bearing mice
was found (Fig. 5A). Chronic NaHS injections seemed to have
low incidence on the general condition of the mice, as no
deterioration in body weight was observed as compared with
vehicle-treated mice during the experiment (Fig. 5B).
Prolonged exposure toNaHSexhibits opposite effects on cancer
cell proliferation depending on the extracellular pH
Some reports have already investigated the intrinsic antican-
cer properties of H2S. Under different circumstances, H2S acts
as an inhibitor or as a promoter of proliferation for various cell
types (27). It is currently hypothesized that conﬂictual conclu-
sions arise from the manner in which cells are exposed to the
treatment. We investigated whether pHe could play a role in the
effects of NaHS on cancer cell proliferation. For the purpose,
MDA-MB-231 cancer cells were incubated with 50 mmol/L
NaHS in alkaline (pH 7.4) or acidic (pH 6.5) media during
4 hours. Proliferation was assessed using quantitation of BrdU
incorporated in the DNA of the cells during incubation. Our
results showed opposite effects of NaHS depending on pHe
(Fig. 6A). In the presence of an alkaline pHe, DNA synthesis in
NaHS-treated cells increased, as compared with nontreated
cells. In contrast, a decrease in DNA synthesis was induced by
the H2S donor when cells were incubated in an acidic medium.
The decreased proliferation found in cells incubated at low pHe
was not associated with cell mortality (Supplementary Fig. S2).
Further experiments were conducted to help understand the
complex role of H2S in cancer cell proliferation. We found that
reactive oxygen species were not implicated in the pro- or
antiproliferative effects of NaHS (Supplementary Fig. S3). We
then asked whether a glycolytic switch occurred in the NaHS-
treated cells. Indeed, enhanced glycolysis is known to confer
advantages for cancer cell proliferation by providing reductive
equivalents and glycolytic intermediates that fuel important
biosynthetic reactions and promote cell expansion (28–30). We
found a signiﬁcant increase in glucose consumption (Fig. 6B) in
NaHS-treated cells compared with nontreated cells in the
alkaline condition, seemingly induced to maintain ATP
homeostasis (Fig. 6C) in compensation to inhibition of the
mitochondrial function. Supporting our ﬁndings, others haveFigure 4.
NaHS in combination with radiotherapy increases the radioresponse of
MDA-MB-231 tumors. A, tumor growth curves of mice treated with NaHS
(100 mmol/kg,&) or vehicle (NaCl 0.9%,&) alone, 16 Gy of radiotherapy
15 minutes after NaHS (*) or vehicle (*) injection, and 16 Gy of
radiotherapy 15 minutes after NaHS injection plus ligation at the time
of irradiation (~). Each point represents the mean tumor size  SEM.
B, regrowth delay expressed as the time to reach a tumor size of 12 mm.
 , P < 0.05; , P < 0.01; ns, not signiﬁcant. ANOVA and Bonferroni
post-test (n ¼ 6/group).
Figure 5.
NaHS injected chronically is inactive on MDA-MB-231 tumor growth.
Tumor growth (A) and body weight (B) of mice treated daily with NaHS
(100 mmol/kg/day, &) or vehicle (NaCl 0.9%, &). Each point represents
mean  SEM (n ¼ 4/group).
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also reported that a synthetic H2S donor promotes an inﬂux of
glucose and triggers enhanced glycolysis in another human
breast cancer cell line (31). We then analyzed the decreased
proliferation induced by NaHS in the acidic condition. By
noticing that low pHe itself had profound impact on cancer
cell proliferation, we questioned whether NaHS treatment was
able to exacerbate the acidic stress experienced by cancer cells at
low pHe. Indeed, it was recently evidenced that, besides its
ability to enhance glycolysis, H2S also impairs the activity of pH
regulators in cancer cells, leading to the intracellular accumu-
lation of acid and reduction of pHi (31, 32). It is also known
that pHi must be kept in a narrow range, otherwise cell-cycle
progression and biosynthetic processes are compromised (33).
By measuring pHi in MDA-MB-231 cancer cells, we observed
that 4 hours of exposure to an acidic pHe decreased pHi and
that an additional effect was found when NaHS was added
(Fig. 6D).
Discussion
In this study, we showed that H2S used as cotreatment to
radiotherapy, but not as single treatment, provided beneﬁcial
effects for cancer therapy.
Clinical investigation has demonstrated that tumor hypoxia,
arising from an imbalance between oxygen consumption and
blood supply, is a major cause of resistance to radiotherapy.
Therefore, selective targeting of cellular oxidative metabolism
and/or tumor perfusion is challenging to radiosensitize tumors.
For the ﬁrst time, we report that administration of an H2S donor
(NaHS) before radiotherapy improves tumor oxygenation and
radiosensitivity. Our results suggest that NaHS rapidly reduces
tumor hypoxia by decreasing oxygen consumption by tumor cells
and by increasing oxygen delivery by the tumor vasculature.
Human cancer cells treated with NaHS exhibited a decreased
OCR that was dose and pH-dependent. The potentiating effect
of an acidic pHe on OCR inhibition by NaHS is of particular
interest, as hypoxic areas are generally associatedwith lowpHdue
to cellular adaptations (28, 34) so that pHe values as low as 6.5
have been observed in human tumors (35). Several mechanisms
may be implicated in the enhanced inhibitory effect of NaHS on
OCR at low pHe. First, as H2S dissociates to form HS
 þHþ ions
with a pKa close to 7, acidosis shifts the balance to the uncharged
(H2S) form, which is permeant to the cell membrane (25). Also,
Nicholls and Kim have demonstrated that cytochrome C oxidase
inhibition by H2S is pH-dependent (Ki values ranging from 2.6
mmol/L to 0.07mmol/L at pHof 8.05 to 6.28, respectively; ref. 36).
We also observed that when incubated in the same experimental
conditions, OCR inhibition by NaHS was more efﬁcient in MDA-
MB-231 cancer cells than in SiHa cancer cells. In vivo, a major
increase in pO2was also found inMDA-MB-231 tumors following
NaHS treatment. These different sensitivities may involve the
capacity of cells to metabolize H2S. It has been mathematically
demonstrated (37) and experimentally validated (38) that target-
ing oxygen consumption was the most effective way to reduce
tumor hypoxia. Therefore, the different cellular response observed
in OCR experiments may account for the greater increased pO2
found in MDA-MB-231 tumors following NaHS injection.
We also studied the effect of NaHS on tumor perfusion. At ﬁrst
glance, as H2S induces vasorelaxation in numerous types of
blood vessels (3), it would appear that a systemic administration
of H2S would lead to a negative response in tumor perfusion
because of the so-called "steal effect" (39). However, our results
showed that NaHS injected in the systemic circulation of the
mice increased tumor perfusion in two tumor models. The fact
that the vasoactive effects of H2S are oxygen-dependent may play
a beneﬁcial role on the vascular response of hypoxic tumors.
Indeed, both chronic and intermittent hypoxia increase the
expression of KATP channels (40), the principal vascular target of
Figure 6.
pHe-dependent opposite effects of NaHS on MDA-MB-231 cancer cell
proliferation. Cancer cells were incubated with 50 mmol/L NaHS or vehicle
(NaCl 0.9%) in the presence of different pHe values during 4 hours. A,
proliferation rates were analyzed by incorporation of a nucleotide analogue
(BrdU) in the DNA of the cells during the incubation. B, glucose consumption
was evaluated by measuring extracellular glucose concentrations before and
after the 4-hour incubation in the presence of pHe¼ 7.4. C, intracellular ATP
level was quantiﬁed using a luciferase-based method after the 4-hour
incubation in the presence of pHe ¼ 7.4. D, pHi was measured using a
ﬂuorescent pH indicator. Each bar represents mean  SEM.  , P < 0.05;
 , P < 0.001; ns, not signiﬁcant. Two-sided t test (n  3).
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H2S (3). Moreover, it has been reported that H2S induces vasor-
elaxation much faster at below physiologic O2 levels (41).
Aswe showed thatNaHS increases tumor pO2by targeting both
cancer cells metabolism and tumor perfusion, we then conducted
radiosensitizing experiments in the MDA-MB-231 tumor model
to test the therapeutic value of the use of NaHS in combination
with radiotherapy. There was a signiﬁcantly increased radiore-
sponse of the tumors when irradiation was applied 15 minutes
after NaHS injection, time at which tumor reoxygenation
occurred. Conﬁrming that the oxygen level is an important factor
for radiosensitization by the H2S donor, tumors that were
clamped during the irradiation were not radiosensitized.
One area related to H2S treatment for cancer that has already
been studied is the effect on proliferation and survival. Changes in
the expression of endogenous H2S-producing enzymes (11) or
exogenous administration of H2S donors (8–10) suggest that H2S
controls tumor progression. Here, we studied the impact of pHe
on the cellular response to prolonged exposure to NaHS. At pHe
of 7.4, the H2S donor increased glucose consumption. Enhanced
glucose uptake was likely induced in cancer cells to compensate
the ATP depletion due to the mitochondrial inhibition observed
in these experimental conditions. Because enhanced glucose
metabolism is known to promote cancer cell proliferation (28,
29), increased glycolysis by NaHS could potentially account for
the increased DNA synthesis rate observed in our study. On the
other hand, as H2S also impaired pHi homeostasis, NaHS exhib-
ited antiproliferative effects when cells were incubated at lower
pHe. Taken together, our results emphasize how external factors
inﬂuence cell response to H2S.
The chronic injection of NaHS in mice did not provide signif-
icant effect on tumor growth, probably because of the microen-
vironmental heterogeneities characteristic of solid tumors, such as
pH gradients. Using xenografts of leukemia cells in mice, others
have evidenced the efﬁcacy of a synthetic H2S donor to restrain
tumor growth (10). On the contrary, silencing of the H2S-pro-
ducing enzyme cystathionine-b-lyase decreased tumor growth
(11). Further experiments with increasing dose of NaHS injected
more repeatedly or intratumorally may highlight pro- or antican-
cer properties in vivo. Our experiment suggested a good tolerance
of themice to daily 100 mmol/kg NaHS administration, but more
accurate monitoring of in vivo toxicity should be considered,
especially in dose escalation experiments. Finally, as we showed
that the antiproliferative effect of NaHS arises at low pH, more
advanced tumors may be more sensitive to the treatment.
In conclusion, we report that NaHS, a fast H2S-releasing donor,
enhances radiotherapy efﬁcacy by alleviating hypoxia in solid
tumors. The good tolerance of the mice to chronic NaHS admin-
istration further pleads in favor of preclinical evaluation of the
combination of H2S donors to fractionated radiotherapy. When
considering H2S as single treatment for cancer, we report para-
doxical effects of H2S on cancer cell proliferation depending on
external pH and no therapeutic beneﬁts in vivo. Therefore, we
suggest a new approach for the use of H2S donors in combination
therapy
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